Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue SUPPL.2, 2013, Pages

  Montravers, Philippe ^a   Bassetti, Matteo ^b   Dupont, Hervé ^c   Eckmann, Christian ^d   Heizmann, Wolfgang R ^e   Guirao, Xavier ^f,g   García, Miguel Sánchez ^h   Capparella, Maria Rita ⁱ   Simoneau, Damien ⁱ   Bodmann, Klaus Friedrich ^j  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^d Klinikum Peine   (France)

^e Center for Microbiology and Infectious Diseases   (Germany)

^f HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^g UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^h UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

ⁱ PFIZER INC   (United States)

^j Werner Forssmann Hospital   (Germany)

more..

Author keywords

Broad spectrum antibacterial therapy; Glycylcycline antibiotics; Necrotizing skin infections; Non interventional studies

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GLYCOPEPTIDE; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ABSCESS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; CELLULITIS; CLINICAL PRACTICE; COMORBIDITY; COMPLICATED SKIN AND SOFT TISSUE INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; FRANCE; GERMANY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; ITALY; KIDNEY DISEASE; LIMB; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NECROSIS; OBSERVATIONAL STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SKIN INFECTION; SOFT TISSUE INFECTION; SPAIN; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BROAD-SPECTRUM ANTIBACTERIAL THERAPY; GLYCYLCYCLINE ANTIBIOTICS; NECROTIZING SKIN INFECTIONS; NON-INTERVENTIONAL STUDIES;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879350590     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt141     Document Type: Article

References (31)

1. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65 Suppl 3: iii35-44.
2. May AK, Stafford RE, Bulger EM et al. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt) 2009; 10: 467-99.
3. Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl 1: i3-17.
4. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998- 2004). Diagn Microbiol Infect Dis 2007; 57: 7-13.
5. Rajan S. Skin and soft-tissue infections: classifying and treating a spectrum. Cleve Clin J Med 2012; 79: 57-66.
6. Namdari H, Tan TY, Dowzicky MJ. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline Evaluation and Surveillance Trial, 2004-2009. Int J Infect Dis 2012; 16: e60-6.
7. Edelsberg J, Berger A, Weber DJ, et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008; 29: 160-9.
8. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 Suppl 5: S315-32.
9. Dowzicky MJ. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the Tigecycline Evaluation and Surveillance Trial (TEST) between 2004 and 2009. Clin Ther 2011; 33: 1964-73.
10. Andrasevic AT, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004-2009). Int J Antimicrob Agents 2012; 39: 115-23.
11. Tygacil Summary of Product Characteristics. Sandwich, Kent, UK: Pfizer Ltd, 2012.
12. Stein GE, Smith CL, Missavage A, et al. Tigecycline penetration into skin and soft tissue. Surg Infect (Larchmt) 2011; 12: 465-7.
13. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-66.
14. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-61.
15. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycinaztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
16. US FDA. FDA Drug Safety Communication: Increased Risk of Death With Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections (1 September 2010). http://www.fda.gov/drugs/drugsafety/ucm224370.htm (26 September 2012, date last accessed). (1 September 2010).(26 September 2012, date last accessed)
17. Cai Y, Wang R, Liang B, et al. Systematic review and metaanalysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55: 1162-72.
18. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-44.
19. Vardakas KZ, Rafailidis PI, Falagas ME. Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis 2012; 54: 1672-4.
20. Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-71.
21. European Medicines Agency. EPAR Summary for the Public: Tygacil (last updated February 2012). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000644/WC500044509.pdf (6 November 2012, date last accessed).
22. Bodmann KF, Heizmann WR, von Eiff C, et al. Therapy of 1025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities. Chemotherapy 2012; 58: 282-94.
23. Eckmann C, Heizmann WR, Leitner E, et al. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice. Chemotherapy 2011; 57: 275-84.
24. Bassetti M, Nicolini L, Repetto E, et al. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010; 10: 287.
25. Montravers P, Dupont H, Bedos JP, et al. Use of tigecycline in intensive care: a French prospective observational study. Clin Microbiol Infect 2012; 18: 767-8.
26. Sanchez Garcia M, on behalf of the Tigecycline in Critically Ill Patients Study Group. Observational study of the use of tigecycline (TGC) in critically ill patients (CIP). In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2011. Abstract K-1412. American Society for Microbiology, Washington, DC, USA.
27. Bassetti M, Eckmann C, Bodmann KF, et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii5-14.
28. Heizmann WR, Dupont H, Montravers P, et al. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii45-55.
29. Guirao X, Sánchez García M, Bassetti M, et al. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii37-44.
30. Reygaert WC. Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline. Ther Clin Risk Manag 2010; 6: 419-30.
31. French Society of Anesthesia and Intensive Care. Scoring Systems for ICU and Surgical Patients: APACHE II (Acute Physiology And Chronic Health Evaluation). http://www.sfar.org/scores2/apache22.html (12 February 2013 date last accessed).